Clinical Trial Update: Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ET [Phase 2]

View source ↗

Summary

Phase 2 trial assessing peginterferon alfa-2b for hydroxyurea-resistant or intolerant essential thrombocythemia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Thrombocythemia

Drugs mentioned

• Peginterferon alfa-2b (Peginterferon alfa-2b)

Snippet

Sponsor: Xiamen Amoytop Biotech Co., Ltd. | Conditions: Essential Thrombocythemia | Phase 2 | Status: RECRUITING